Protocol Ledger

NCT05862285 · Phase III · RECRUITING

A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

Interventional Phase III clinical trial protocol NCT05862285 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-06-01 Enrollment: 100 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05862285
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)100 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05862285
Protocol FieldVerified Registry Value
NCT IdentifierNCT05862285
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment100 participants (ESTIMATED)
Registered Start Date2023-06-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05862285
Hospital Research SiteLocationSite Profile
AZ GroeningeKortrijk, BelgiumOpen Hospital Dossier ->
Fudan University Shanghai Cancer CenterShanghai, ChinaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI